Study on Sulfasalazine for Malignant Gliomas
Author Information
Author(s): Robe Pierre A, Martin Didier, Albert Adelin, Deprez Manuel, Chariot Alain, Bours Vincent
Primary Institution: University of Liège
Hypothesis
Sulfasalazine should be well tolerated by patients with recurrent or progressive malignant glioma and could inhibit tumor progression.
Conclusion
The study aims to evaluate the safety and efficacy of Sulfasalazine in treating malignant gliomas.
Supporting Evidence
- Sulfasalazine has been shown to inhibit the growth of glioblastoma cells.
- The study is designed to assess the safety and efficacy of Sulfasalazine in patients with malignant gliomas.
- Patients will be monitored for adverse events and tumor response.
Takeaway
This study is testing a medicine called Sulfasalazine to see if it can help people with a type of brain cancer called malignant gliomas.
Methodology
A phase 1–2, single center, prospective, randomized, double blind study with 20 patients assigned to different dosages of Sulfasalazine.
Potential Biases
Potential bias in patient selection and reporting of adverse events.
Limitations
The study is limited to a small sample size and specific patient demographics.
Participant Demographics
Adult patients (age > 18) with recurrent or progressive WHO grade 3 or 4 astrocytic gliomas.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website